https://www.sciencedirect.com/science/article/abs/pii/S0165247820303618?via%3Dihub
https://www.ncbi.nlm.nih.gov/pubmed/32781006?dopt=Abstract
LncRNA GAS5 supresses CD4+ T cell activation by upregulating E4BP4 via inhibiting miR-92a-3p in systemic lupus erythematosus.
Immunol Lett. 2020 Aug 08;:
Authors: Liu Q, Deng Y, Li C, Xie H, Liu Q, Ming S, Wu D, Luo F
Abstract
Increasing evidence reveals that long noncoding RNAs (lncRNAs) are associated with autoimmune and inflammatory diseases, such as systemic lupus erythematosus (SLE). In this study, we aimed to explore the role of lncRNA growth arrest specific 5 (GAS5) in the pathogenesis of SLE. We found that lncRNA GAS5 was decreased in CD4+ T cells and plasma from SLE patients. Overepression of GAS5 inhibited activation of normal CD4+ T cells and attenuated the self-reactivity of SLE CD4+ T cells. Additionally, we demonstrated that adenovirus E4 binding protein 4 (E4BP4) was involved in lncRNA GAS5-mediated inhibition of CD4+ T cell activation. GAS5 could upregulate E4BP4 by inhibiting miR-92a-3p. Taken together, our results indicate that the GAS5/miR-92a-3p/E4BP4 pathway plays an important role in inhibiting CD4+ T cell activation in SLE, thus providing a potential therapeutic target for SLE treatment.
PMID: 32781006 [PubMed – as supplied by publisher]
PubMed:32781006
Date Found:
08/12/20 06:02AM
